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Regulators of G-protein signaling (RGS) accelerate
guanine triphosphate hydrolysis by Ga-subunits
and profoundly inhibit signaling by G protein-cou-
pled receptors. The distinct expression patterns
and pathophysiologic regulation of RGS proteins
suggest that inhibitors may have therapeutic
potential. We previously reported the design of a
constrained peptide inhibitor of RGS4 (1: Ac-Val-
Lys-[Cys-Thr-Gly-Ile-Cys]-Glu-NH2, S-S) based on
the structure of the Gai switch 1 region but its
mechanism of action was not established. In the
present study, we show that 1 inhibits RGS4 by
mimicking and competing for binding with the
switch 1 region of Gai and that peptide 1 shows
selectivity for RGS4 and RGS8 versus RGS7. Struc-
ture–activity relationships of analogs related to 1
are described that illustrate key features for RGS
inhibition. Finally, we demonstrate activity of the
methylene dithioether-bridged peptide inhibitor, 2,
to modulate muscarinic receptor-regulated potas-
sium currents in atrial myocytes. These data sup-
port the proposed mechanism of action of peptide
RGS inhibitors, demonstrate their action in native
cells, and provide a starting point for the design
of RGS inhibitor drugs.
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When activated by an agonist, a G protein-coupled receptor
(GPCR) stimulates exchange of guanine triphosphate (GTP) for
guanine diphosphate (GDP) on the Ga-subunit of the G protein,
which then undergoes an activating conformational change that
allows it and its associated bc-subunit to interact with effector
proteins (1). The Ga-subunit inactivates itself by hydrolyzing GTP
to GDP followed by reassociation with Gbc. Regulators of G-pro-
tein signaling (RGS) proteins are GTPase accelerating proteins
(GAPs) for Ga-subunits (1). They bind to the activated Ga protein,
stabilize the transition state for GTP hydrolysis without directly
interacting with the nucleotide (2), accelerate GTP hydrolysis and
inactivation of the G protein, and inhibit cell responses to GPCR
signaling.
There are 20 classical RGS proteins and at least 16 RGS homology
(RH) domains identified in the human genome (3). The RGS proteins
have some Ga specificity (1), some receptor specificity (4–7), and
unique expression patterns (8–10). Because of this, an RGS inhibitor
could selectively potentiate GPCR signaling in specific tissues or
brain regions (11,12). Many disease states have been attributed to
defects in cell signaling including Parkinson's disease and Alzhei-
mer's disease (13). An RGS inhibitor that could, for example,
increase dopamine or acetylcholine responses in specific brain
regions may have significant therapeutic potential on its own or
might enhance effects of existing agonists in a tissue-specific man-
ner to reduce side-effects (11,12). RGS proteins have also been pro-
posed as therapeutic targets in the treatment of diabetes (14),
opioid tolerance (3), heart failure (15), asthma (16), and cancer (17).
The RGS proteins are divided into several families based on the
homology of the 120 amino acid RGS domain as well as the pres-
ence or absence of other domains (1). Members of the R4 family of
RGS proteins are primarily composed of the RGS domain and a
short amphipathic N-terminus that plays a role in membrane target-
ing and/or receptor specificity (18–20). RGS4 is the prototypical
member, and the first member of this family for which there was
an X-ray crystal structure (21). It also has roles in cardiovascular
and central nervous system signaling and was the starting point for
our RGS inhibition efforts.
We previously reported the design of a peptide inhibitor of RGS4
(1: Ac-Val-Lys-[Cys-Thr-Gly-Ile-Cys]-Glu-NH2, S-S, where S-S indi-
cates disulfide cyclization through the Cys side chain sulfur atoms)
based on the structure of the switch 1 region of activated Gai1
(22). Peptide 1 was designed to bind to RGS in the same way that
Gai1 binds in order to prevent Ga/RGS interactions, and, indeed, 1
inhibited RGS4 activity in a membrane-based steady-state GTPase
assay with an IC50 of 26 lM (22). Further, 1 has been shown to
inhibit RGS4 and RGS8 activity in a capillary electrophoresis
pseudo-single turnover GTPase assay (23).
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In the present study, we extend these observations to quantify the
activity of RGS inhibitor peptides in true single turnover [32P]GTPase
studies with purified Ga and RGS proteins. In addition, we examine
structure–activity studies to define key features of active peptides,
test the mechanism of peptide 1-mediated RGS inhibition by use of
the Gai Gly183Ser mutant, determine the specificity for different RGS
proteins, and demonstrate effects of an analog on the kinetics of acet-
ylcholine-stimulated GIRK currents in patch-clamped atrial myocytes.
Materials and Methods
Materials
Fmoc-protected amino acids and Rink amide resin were purchased from Advanced
ChemTech (Louisville, KY, USA). Preloaded PEG-PS resin, the ABI 431A automated pep-
tide synthesizer, and peptide grade synthesis chemicals were purchased from Applied
Biosystems (Foster City, CA, USA). c[32P]GTP (10 mCi/mL) was purchased from Amer-
sham (Piscataway, NJ, USA), or from Perkin-Elmer (Boston, MA, USA) and diluted in
unlabeled GTP to the desired level of radioactivity.
Protein expression and purification
His6-Gao (rat), His6-RGS4 (rat), glutathione S-transferase (GST)-RGS7box (human, nucle-
otides 915–1359), and GST-RGS8 (rat, nucleotides 315–857) were expressed and puri-
fied according to previous protocols (24–26).
Peptide synthesis
Peptides were synthesized and cyclized as described previously (22). Resin was treated
with piperidine (Aldrich, Milwaukee, WI, USA) to cleave the Fmoc-protecting group, then
the first amino acid was coupled with o-benzotriazol-1-yl-N,N,N',N'-tetramethyl uronium
hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole (HOBt; Applied Biosystems). Tri-
fluoroacetic acid (TFA)/water/dithioethane (90:5:5) or TFA/phenol/water/triisopropylsilane
(88:5:5:2) was used to cleave the linear peptide from the resin and simultaneously remove
the side chain-protecting groups. The peptide solution was filtered from the resin and
then subjected to preparative reverse-phase high-performance liquid chromatography (RP-
HPLC) to afford the linear disulfhydryl-containing peptide with a purity of at least 90%.
Cyclization of linear peptides
For disulfide formation, linear disulfhydryl-containing peptides were dissolved (1 mg/mL)
in 1% acetic acid, 0.1% TFA, 2 M urea in N2 saturated water on ice. The pH of the peptide
solution was raised to 8.5 using NH4OH, followed by the addition of 4 mol equivalents of
K3Fe(CN)6. The reaction mixture was stirred for 1 min, and quenched with acetic acid to a
pH of 3.5 or less. The mixture was then subjected to HPLC.
To form dithioether or dithiomethyl-containing cyclic peptides, a linear disulfhydryl pep-
tide was added to a dimethylformamide solution cooled in an ice bath under a N2
atmosphere (0.1 mg linear peptide/mL dimethylformamide). About 5 mol equivalents of
potassium t-butoxide were added to the peptide solution, followed by the addition of
2.5 mol equivalents of Br-(CH2)n)Br (n ¼ 1 or 2). The reaction was quenched with
2 mL acetic acid after 2 h and the solvent was removed in vacuo. The residue was dis-
solved in water, filtered, and then subjected to HPLC.
All final product peptides were at least 95% pure as assessed by RP-HPLC on a Vydac
218TP C-18 column (The Nest Group, Southboro, MA, USA) using the solvent system
0.1% TFA in water/0.1% TFA in acetonitrile by a gradient of 0–90% organic compo-
nent in 90 min. All peptides displayed the appropriate molecular weights as deter-
mined by electrospray ionization (ESI) mass spectrometry.
RGS-stimulated GTPase
Single turnover GTP hydrolysis measurements with and without RGS were based on
Lan et al. (25) and adapted to a 96-well plate format. Briefly, 200–800 nM Gao was
loaded with a two- to threefold molar excess of c[32P]GTP in 20 mM HEPES, 20 mM
ethylenediaminetetraacetic acid (EDTA) pH 8.0 for 5 or 20 min at room temperature
and then cooled on ice. In some cases, the loaded Gao was gel filtered through a
1 mL G-25 Sephadex spin column to remove unbound [32P] GTP. The loaded Gao was
then added to equal volumes of ice-cold initiation buffer (20 mM HEPES, 40 mM MgCl2
pH 8.0 and 5–20 lM unlabeled GTP) containing RGS and/or peptide1. The concentra-
tion of RGS protein (15–500 nM) was varied to keep the uninhibited rate of GTP hydro-
lysis <5.5 per min. This variation in RGS concentration was needed because of
different activities of the protein preparations, different activities of the various RGS
proteins against Gao, and different concentrations of Gao used. After incubation for
various times on ice, the reaction was quenched with 5% activated charcoal in buffer-
containing 20 mM sodium phosphate buffer (pH 2.0). After 20 min, the charcoal was
centrifuged and the supernatant counted in a Perkin-Elmer TopCount 96-well plate
counter by Cerenkov counting. The amount of [32P]Pi released at each time-point was
fit to an exponential function:
½32PPicountsðtÞ¼countsðt¼0ÞþDcountsðt¼30minÞð1ektÞ
The rate constant (k) was calculated using GraphPad Prism (San Diego, CA, USA). Fit-
ting constraints included setting counts(t¼0) for each curve to the average of the
counts(t¼0) for the experiment, and setting counts(t¼30min) to the same value for all
curves in an experiment. Peptide activity is determined from the percentage decrease
in RGS-stimulated GTPase rate constant (k).
Electrophysiology
All animal studies were performed properly following the guideline of the ethical
committee of Osaka University Graduate School of Medicine. Single rat atrial myo-
cytes were enzymatically isolated from hearts removed from adult male Wister–Kyoto
ats as described elsewhere (27). Briefly, rats were deeply anesthetized by i.p. injec-
tion of pentobarbital. A cannula was inserted into the aorta, and the heart was per-
fused in a retrograde manner through the coronary arteries. The heart was digested
by collagenase (Roche Diagnostics, Basle, Switzerland) in nominally Ca2+-free solution
at 37 C for 10 min. Dissociated myocytes were seeded on glass coverslips (15 mm
diameter) which had been coated with poly-D-lysine (Sigma, St Louis, MO, USA) kept
in a humidified environment of 0.5% CO2 at 37 C, and cultured with medium M199
(PAA Laboratories, Linz, Austria) containing gentamycin and kanamycin (25 mg/L each)
for 2–4 days. Muscarinic receptor-regulated KG channel (GIRK) currents in atrial
myocytes were measured using whole-cell mode patch-clamp method as previously
described (27). The whole-cell currents were measured at room temperature by a
patch-clamp amplifier (Axon 200A, Axon Inst., Sunnyvale, CA, USA) and recorded on
videocassette tape with a PCM converter system (VR-10B, Instructech, Port Washington,
NY, USA). Data were analysed with commercially available software (Patch Analyst Pro,
MT Corporation, Los Angeles, CA, USA) after low-pass filtering at 1 kHz ()3 dB) by an
eightpole Bessel filter, sampled at 5 kHz. The control bathing solution contained (in mM):
115 NaCl, 20 KCl, 1.8 CaCl2, 0.53 MgCl2, 5.5 glucose, and 5.5 HEPES-NaOH, pH 7.4. The
pipette (internal) solution contained (in mM): 150 KCl, 5 EGTA, 1 MgCl2, 3 K2ATP, 0.1
Na2GTP, and 5 HEPES-KOH (pH 7.3). The ACh-induced GIRK currents were obtained by
digitally subtracting currents recorded under control conditions from those recorded in
the presence of ACh. Three parameters of RGS action on GIRK currents, i.e. time–course
of onset (kon) and offset (koff) of KG current and degree of relaxation (Iins/Imax), were
determined (27). Peptide 2 was applied intracellularly through the patch capillary elec-
trode. Peptide 2 was first dissolved into dimethlysulfoxide (DMSO) as 15 mM stock, and
then diluted at 1/100 into patch electrode internal solution (final internal solution con-
tained 150 lM peptides and 1% v/v DMSO).
Statistical analysis
Data are expressed as mean € SEM and analyzed by either a two-tailed unpaired
t-test or a one-way ANOVA with a Dunnett's post-test. Significance is indicated as fol-
lows: *p < 0.05, **p < 0.01, ***p < 0.001.
Peptides were added from a 5 mM stock in DMSO resulting in a final
DMSO concentration of 2% or less which was kept constant for all samples
in a given experiment. To avoid precipitation, peptides were never used at
concentrations above half of their aqueous solubility limit as determined by
HPLC.
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Results
Peptide 1 inhibits RGS4 GAP activity in a single
turnover GTPase assay
We previously showed that 1, a constrained peptide mimetic of the
switch 1 region of Gai (Table 1), inhibits RGS4 activity in a steady-
state membrane receptor GTPase assay (22). To confirm that 1 is
interacting with the RGS4 protein rather than other proteins or
lipids in the membrane preparation, we performed single turnover
GTPase assays with purified proteins. RGS4-enhanced hydrolysis of
Gao-bound c[
32P]GTP was measured in the presence and absence of
1. RGS4-stimulated Gao GTPase activity is inhibited by 1 in a dose-
dependent manner (Figure 1) with an IC50 of 9 lM. It should be
noted that peptide 1 was tested up to only 40 lM (i.e. less than
half of its aqueous solubility limit) in order to avoid aggregation.
Consistent with our previous results in a membrane GTPase assay
(22), the methylene dithioether-bridged peptide 2, was active but
had lower potency than did the disulfide-bridged peptide 1 (Table 1).
Gly183 is critical for peptide-mediated
inhibition of RGS4 GAP activity
It is possible that peptide 1 could bind to either the Ga-subunit
or RGS4. In order to determine the target of our peptide inhibi-
tors, peptide 3 was made to mimic the RGS-insensitive
Gly183Ser mutant of Gai. If peptide 1 binds to RGS4 in the
same manner that the switch 1 region of Gai binds, then a
mutation that disrupts this binding in the Gai-subunit should also
disrupt binding of peptide 1. As predicted, peptide 3 does not
inhibit RGS4 activity at a concentration that is nearly four times
greater than peptide 1 (150 lM; Figures 2 and 3A), suggesting
that 1 binds to RGS4 in a competitive manner with the Ga-
subunit. We also prepared peptide 4 using D-Ser in place of the
Gly, as D-Ser (unlike L-Ser) is compatible with the b-turn present
in the Ga switch 1–RGS4 contact. Interestingly, 4 displayed
similar inhibitory properties as 1 in a steady-state GTPase assay
(4, Table 1 and Figure 3A). A D-Pro analog, 5, was ineffective
at inhibiting RGS4 activation of Gao, confirming that the struc-
ture of the constrained peptide is important (Table 1 and Fig-
ure 3A). This is not surprising as Gly183 is important for Gai–
RGS4 interactions (25).
Structure–activity relationship results
In order to better understand which structural components of 1
contribute to its activity, and in hope of identifying more potent
inhibitors, several additional modifications to the structure of 1
were examined. The inhibition of RGS4 GAP activity by each pep-
tide at 100 lM concentration2 was measured using the single turn-
over GTPase assay and the data are summarized in Table 1. By
comparison, 1 inhibits RGS4-stimulated GTPase activity by 75 € 3%
at 40 lM (p ¼ 0.0004 compared with control).
In compound 1, incorporation of the N-terminal acetyl and C-ter-
minal carboxamide was chosen to best correspond to the internal
'parent' sequence in Gai. In order to examine whether such
electrically neutral termini and the octapeptide framework of 1 are
optimal, peptides 6–11 were prepared. As shown in Table 1, ana-
logs with a free N-terminal amine (6) or a C-terminal carboxylate
(10) were inactive (Table 1 and Figure 3B). Truncation of the pep-
tide from either the amino-terminal (7) or carboxy-terminal (11) end
also abolishes activity (Table 1 and Figure 3B). N-terminal elonga-
tion of the peptide by either the previous 1 or 3 amino acids in the
sequence of Gai1 (compounds 8 and 9, respectively) also resulted
in complete loss of activity (Table 1 and Figure 3B). These suggest
that the peptide length and the absence of charged termini are crit-
ical for peptide activity.
The Thr182 of Gai makes several contacts with RGS4 including
interactions with polar (Glu87, Asp163) and non-polar (Leu159) side
chains (21). It is therefore not surprising that changing the Thr of 1
to Ala, lacking the polar hydroxyl group, decreases activity (13,
53 € 10% inhibition of RGS activity at 100 lM, Table 1 and
Figure 3C), while the more conservative Ser substitution has inter-
mediate activity (12, 73 € 3% inhibition of RGS4 activity at
100 lM; Table 1 and Figure 3C). Substitution of Lys for Thr, with
the intention of facilitating a salt bridge with Glu87 of RGS4, was
unsuccessful, demonstrating very low inhibitory activity (14, Table 1
and Figure 3C).
The structure/conformation of the peptide cycle is also important
for activity. In agreement with earlier studies (22), increasing the
cycle size from the disulfide of 1 to the methylene dithioether
bridge of 2 reduces potency. The latter peptide inhibited RGS4
activity by 25 € 7% at 100 lM. Thus, the estimated IC50 for 2 is
approximately 300 lM, significantly less potent than the disulfide-
bonded peptide 1 (Figure 3 and Table 1). Substitution of either
disulfide bridge Cys by the more rigid penicillamine (Pen) resulted
in complete loss of activity (15, 16; Table 1 and Figure 3C). Substi-
tution of the second Cys with D-Cys also resulted in a complete
loss of peptide activity (17, Table 1 and Figure 3C). Linear peptides
have no activity (22; data not shown).
The Ile184 residue of Gai appears to form a van der Waals contact
with Tyr84 of RGS4. We found that other hydrophobic residues at
this position (18, 19, 20, 21) also had some activity (Table 1 and
Figure 3C). In particular, peptides with substitution of Met (18 and
19) inhibit RGS4 activity by 22 € 9% and 61 € 11% at 100 lM
(Table 1 and Figure 3C), and Phe (20 and 21) inhibits 38 € 10 and
52 € 12 at 100 lM and 30 lM, respectively. Interestingly, the ethy-
lene dithioether-bridged 19 and 21 are more active then the disul-
fide-bridged 18 and 20. The opposite is true for the Ile peptides
(22).
Peptides 1 and 2 show RGS specificity
The concentration-dependent effect of 1 on the rate of RGS-stimu-
lated GTP hydrolysis was measured for RGS7 and RGS8 as was
carried out for RGS4. The IC50 of 1 on RGS4, RGS7 and RGS8 is
9 lM, 43 lM and 11 lM respectively (Figure 4A). RGS4 and RGS8
are approximately fourfold more sensitive to 1 than is RGS7. We
have previously examined a series of analogs with the same linear
sequence as in 1, but with larger cycles (effected via dithioether
Roof et al.
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cyclization). In this series, smaller cycles result in more potent pep-
tide inhibitors of RGS4 (22). The methylene dithioether bridged pep-
tide, 2, is the second most potent peptide in this series and
appears to be selective for RGS4 over RGS8 but has no effect on
RGS7 at 100 lM (Figure 4B).
Peptide 2 inhibits RGS regulation of GIRK
currents in cardiac myocytes
To determine whether the peptide inhibitors act in a physiologic
system and to demonstrate a role of RGS proteins in ion-channel
regulation, we used the well-characterized muscarinic GIRK currents
Figure 1: Peptide 1 inhibits RGS4 in a single turnover GTPase assay. The rate of guanine triphosphate (GTP) hydrolysis was measured with no
regulator of G-proteins signaling (RGS; ), 100 nM RGS4 (*), or 100 nM RGS4 with 2.5 lM ( ), 5 lM ( ), 10 lM ( ), 20 lM (•), or with 40 lM (·) 1. This
graph is representative of four experiments carried out in duplicate (mean € SEM).
Table 1: Sequences and RGS4 inhi-






Ga (o, i1, i2, and i3) …180Val-Lys-Thr-Thr-Gly-Ile-Val-Glu187…
1 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 75 € 3 (40)
2 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-CH2-S) 25 € 7
Gly substitutions
3 Ac-Val-Lys-c[Cys-Thr-Ser-Ile-Cys]-GluNH2 (S-S) )10 € 8
4 Ac-Val-Lys-c[Cys-Thr-D-Ser-Ile-Cys]-GluNH2 (S-S) 59 € 4 (30)
5 Ac-Val-Lys-c[Cys-Thr-D-Pro-Ile-Cys]-GluNH2 (S-S) 1 € 14
N-terminal modifications
6 NH2-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 2 € 8
7 Ac-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 8 € 11
8 Arg-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 4 € 9
9 Arg-Thr-Arg-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 13 € 10
C-terminal modifications
10 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluOH (S-S) 1 € 11
11 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-NH2 (S-S) 3 € 29
Thr substitutions
12 Ac-Val-Lys-c[Cys-Ser-Gly-Ile-Cys]-GluNH2 (S-S) 73 € 3
13 Ac-Val-Lys-c[Cys-Ala-Gly-Ile-Cys]-GluNH2 (S-S) 53 € 10
14 Ac-Val-Lys-c[Cys-Lys-Gly-Ile-Cys]-GluNH2 (S-S) 19 € 15
Cys substitutions
15 Ac-Val-Lys-c[Pen-Thr-Gly-Ile-Cys]-GluNH2 (S-S) )9 € 10
16 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Pen]-GluNH2 (S-S) )2 € 2
17 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-D-Cys]-GluNH2 (S-S) 10 € 17
Ile substitutions
18 Ac-Val-Lys-c[Cys-Thr-Gly-Met-Cys]-GluNH2 (S-S) 22 € 9
19 Ac-Val-Lys-c[Cys-Thr-Gly-Met-Cys]-Glu-NH2 (S-CH2CH2-S) 61 € 11
20 Ac-Val-Lys-c[Cys-Thr-Gly-Phe-Cys]-GluNH2 (S-S) 38 € 10
21 Ac-Val-Lys-c[Cys-Thr-Gly-Phe-Cys]-GluNH2 (S-CH2CH2-S) 52 € 12 (30)
a(S-S), (S-CH2-S), (S-CH2CH2-S), indicate cyclization via disulfide, methylene dithioether, and ethylene dithioether,
respectively.
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in atrial myocytes and a whole-cell patch-clamp pipette to deliver
the peptides to the intracellular space. The parent peptide 1 had
no effect on GIRK currents (not shown), presumably because of
residual reducing equivalents in the cell that reduced the essential
disulfide bond. The methylene-bridged peptide 2, however, did
reduce the degree of current relaxation (Figure 5A,Ca) and slowed
the rate of onset and offset of the muscarinic response
(Figure 5B,Cb and d). In some experiments (Figure 5Ab,Bb) the
effect was not seen. Overall, however, there was a statistically




Peptide 1 was designed based on the crystal structure of the
RGS4–Gai complex in the presence of GDPAlF4. The peptide
attempts to mimic the switch 1 region of Gai, a constrained loop
that makes considerable contacts with RGS4. It was designed to
bind to RGS4 and competitively inhibit Ga/RGS interactions and
thus inhibit RGS4 activity. We showed previously that 1 inhibits
RGS4 activity in a steady-state GTPase assay (22) using cell mem-
branes. In the present study, we demonstrated that 1 also inhibits
RGS4 activity in a single turnover GTPase assay using purified pro-
teins. The results of these assays unequivocally demonstrate that 1
is interacting directly with RGS4 protein (or the Gao protein) rather
than with other proteins or lipids found in the membrane prepar-
ation. Jameson et al. recently showed that 1 inhibits both RGS4
and RGS8 in a capillary electrophoresis, pseudo-single turnover
GTPase assay (23), also using purified proteins. It was found in that
system that 1 had a secondary effect of inhibiting the BODIPY-GTP/
Gao interaction; however, that may be an artifact of the BODIPY
fluorophore system, as 1 had little direct effect on the rate of GTP
hydrolysis by Ga in the c[32P]GTP GAP assays (Figure 4A and Ref
22). From this we conclude that 1 is acting directly on the RGS pro-
tein.
To determine whether the mode of interaction of 1 with RGS truly
mimics the Ga-subunit interaction, we designed 3 to mimic the
switch 1 region of the RGS-insensitive Gly183Ser mutant of Gai
(Table 1). The Gly to Ser mutation in the Ga-subunit prevents RGS4
binding (25). We therefore hypothesized that if 1 bound to RGS4
the same way as switch 1 of Gai, then a Gly to Ser modification
would prevent peptide inhibition of RGS4 GAP activity. At almost
four times the maximal concentration of 1 (150 lM), 3 does not
inhibit RGS4 activity (Figure 2), indicating that the Gly in both Ga
and in 1 is essential for binding to RGS4. The Gly to Ser modifica-
tion prevents binding, perhaps due to a direct steric clash of the
Ser side chain with RGS4 or through conformational effects on the
constrained peptide loop. These data further support the notion that
1 mimics the switch 1 region of Ga to block RGS4 activity on Gao.
Figure 2: Gly183 is required for
peptide activity at RGS4. (A) Sin-
gle turnover GTPase assays were pre-
formed as described with no regulator
of G-proteins signaling (RGS; ),
100 nM RGS4 (*), 100 nM RGS4 with
40 lM 1 (·), and 100 nM RGS4 with
150 lM 3 ( ). This graph is represen-
tative of two experiments carried out in
duplicate (mean € SD). (B) Rates were
calculated from the data in (A) as
described. *p < 0.05, **p < 0.01,
***p < 0.001 compared with RGS4
alone.
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Also in support of our proposed mode of action, 1 exhibits signifi-
cant RGS subtype selectivity. Peptide 1 inhibits RGS4 and RGS8 to
a similar extent and inhibits RGS7 less effectively (Figure 4A). RGS4
and RGS8 are both in the R4 family while RGS7 is in the R7 family
(11). This family-selective preference of peptide 1 for RGS4 and
RGS8 supports our conclusion that it binds to the RGS proteins the
same way that Gai binds. Further, 1 has little direct effect on the
catalytic activity of Gao alone (Figure 4 and Ref. 22), from which
we conclude that the peptide inhibitor is directly binding to and
inhibiting the RGS protein, rather than to the Ga protein. Although
Figure 3: Inhibition of RGS4 by analogs of 1. Peptides (from
Table 1) were tested in a single turnover GTPase assay at 100 lM (unless
otherwise indicated) and percentage inhibition of RGS4-stimulated guanine
triphosphate (GTP) hydrolysis rate is shown. The modifications from 1 at the
indicated position are shown after the peptide number. Inhibition of regula-
tor of G-proteins signaling (RGS) activity by peptides with modifications from
1 at the Gly position (A), at the N- or C-termini (B), or at the Thr, Cys or Ile
(C) positions was determined. These graphs are the average of experiments
carried out two to four times (mean € SEM, n ¼ 2–8). *p < 0.05,
**p < 0.01, ***p < 0.001 compared with RGS4 alone.
Figure 4: Peptides 1 and 2 have greater activity for RGS4 and
RGS8 than RGS7. (A) Rate constants were calculated as described in Fig-
ure 1, for no regulator of G-proteins signaling (RGS; h), RGS4 ( ), RGS7
( ), and RGS8 (•) with various concentrations of 1. These graphs are the
average of three (RGS4, no RGS at 40 lM 1), four (RGS7 and RGS8) or five
(no RGS, 0 lM 1) experiments carried out in duplicate (mean € SEM).
*p < 0.05, **p < 0.01, ***p < 0.001 compared with RGS4. (B) Percentage
inhibition of the rate of RGS4-, RGS7-, and RGS8-stimulated guanine tripho-
sphate (GTP) hydrolysis by 100 mM 2 was measured. This is the average of
two to eight experiments carried out in triplicate (mean € SEM, n ¼ 6–10)
*p < 0.05, **p < 0.01, ***p < 0.001 compared with RGS4.
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Figure 5: Inhibition of regulator of G-proteins signaling (RGS) effects on GIRK currents in atrial myocytes by peptide 2. (A) Represen-
tative tracings of currents evoked by 0.1 (left) or 1 (right) lM acetylcholine in the presence (a and b) or absence (c) of 150 lM 2, 1% dimethlysulfoxide (DMSO).
Sections a and b show the variation of responses to peptide 2. Currents at )100 mV were recorded after prepulses to )100 to +40 mV in steps of 20 mV.
Baseline currents at 0 lM acetylcholine were subtracted out. Arrows indicate the end-point of the instantaneous and the start point of the relaxing components
of the currents. Vertical bars represent 500 pA, and horizontal bars indicate 1 second. (B) Representative tracings of deactivation (left) and activation (right) of
GIRK currents in the presence (a and b) and absence (c) of 150 lM 2, 1% DMSO. Sections a and b show the variation of responses to peptide 2. Arrows indi-
cate the end-point of deactivation or activation and the horizontal bar indicates 10 seconds. (C) Ins/Imax, (a), T1
2
(deactivation; b) and T1
2
(activation; c) were cal-
culated in the presence (left) and absence (right) of 150 lM 2 from (A) and (B) and are shown for individual cells. The mean value is indicated with open
circles (n ¼ 5–10 cells).
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it is less potent, 2 appears to have similar RGS selectivity and
likely shares a similar mechanism of action (Figure 4B).
In the present study, we found peptide 1 to have an IC50 of 9 lM
against RGS4 (Figure 4A) while in our previous report, in a mem-
brane steady-state GTPase assay, it was less potent with an IC50 of
26 € 2 lM (22). Peptide 1 inhibited RGS4 81% at 40 lM in a capil-
lary electrophoresis assay with Gao (23) and is in good agreement
with our 75 € 3% inhibition (Table 1). For RGS8, 40 lM 1 inhibited
38% and 74 € 23% in the capillary electrophoresis and our single
turnover GTPase assays, respectively (23; Figure 4A). Both assays
using purified proteins give similar results. However, there are sev-
eral differences between these systems and the membrane-based
steady-state GTPase assay that may contribute to the disparate
activities observed. These include the presence of other proteins
(including endogenous RGS proteins), various G proteins, the pres-
ence of membranes and different temperatures (30 C in the
steady-state assay and ice-cold for the single turnover assay). In
addition, the steady-state and the single turnover GTPase assays
measure different aspects of the GTP cycle and may thus compli-
cate a direct comparison. The difference is even greater for 2
(Table 1). We show here that RGS4 is inhibited 24 € 5 per cent at
100 lM 2 for an IC50 of about 300 lM compared with an IC50 of
79 € 6 lM in the steady-state GTPase assay (22).
Structure–activity relationships of peptide
inhibitors
Although Val179 and Glu186 of Gai do not appear to make direct
contacts with RGS4 (21), these residues, with their N- and C-ter-
minal charges blocked, appear to be necessary for peptide activ-
ity (Table 1). Perhaps the absence of constraints from the rest of
Ga allows these residues and modifiers to make contacts with
RGS4 that the switch 1 of Gai could not normally make. It is
likely that the charges on the free N- or C-termini interfere with
binding to RGS4 via adverse electrostatic interactions and the ter-
minal acetyl and amide groups of 1 prevents these negative
interactions.
The Thr182 of Gai makes contacts with several residues in RGS4
including Glu87 and Asn88 (21). It is therefore not surprising that
changing the Thr of 1 to Ala decreases its activity as an RGS4
inhibitor (13, Table 1 and Figure 3C), while a more conservative
Ser substitution retains considerable activity (12, Table 1 and
Figure 3C). Glu87 and Asn88 of RGS4 form hydrogen bonds with
the hydroxyl group on Thr182 of Gai (21). We expect that similar
interactions are made with the hydroxyl group of Ser in 12. We
proposed that a Lys in this position might interact with Glu87 on
RGS4 and enhance its inhibitory effect; however, the lysine substi-
tution for Thr abolishes activity (14, Table 1 and Figure 3C). It is
interesting to note that Ga12 has a Lys at this position in switch 1,
and is not a substrate for RGS4 GAP activity.
Ile184 of Gai may form a van der Waals contact with Tyr84 of
RGS4. It is therefore not surprising that a peptide with a Met at
this position still retains activity as an RGS inhibitor (Table 1 and
Figure 3C). It is interesting that 19, with an ethylene dithioether
bridge, is more active than 18 with a disulfide bridge. This is also
the case with Phe substitutions for Ile (21 and 20, Table 1 and
Figure 3C). The opposite is true for the peptides with the Ile at this
position (22). Perhaps the alternate conformation of the ethylene
bridge positions the Met to make better contact with the RGS4 pro-
tein. However, neither peptide is as potent as 1.
Peptide RGS inhibitor effects on cardiac GIRK
current
This inhibition of RGS-dependent phenomena in atrial myocytes by
peptide 2 is the first demonstration of the actions of an RGS
inhibitor in a physiologic system. The magnitude of the effect is
only modest but is consistent with the IC50 of this peptide at
RGS4. The 25% inhibition of in vitro single turnover GAP activity
seen at 100 lM 2 (Figure 4B) and the 25–35% inhibition of kon,
koff, and Iins/Imax seen in our patch-clamp studies (Figure 5C) with
150 lM 2 are both consistent with a Ki of about 300 lM. The
RGS proteins known to be expressed in rat atrial myocytes are 2,
3, 4, 6, 10, 17 (RGSZ2), and 19 (GAIP) (28,29). As GIRK currents
are primarily regulated by Gai, (30) and RGS 2, 6, and 17, act pri-
marily on Gaq, Gao, and Gaz, respectively, RGS 3, 4, 10, and 19
are the best candidates for controlling the kinetics of GIRK cur-
rents. Peptide 2 inhibits RGS4 and the sequence similarity of the
RGS domain of these other RGS proteins is quite high (43–61%)
and greater than that for 7 (35%); it is likely that peptide 2 may
inhibit multiple RGS proteins that may be involved in Gai and GIRK
current regulation.
Here, we show modest specificity of our constrained peptide RGS
inhibitors 1 and 2 (RGS4 ‡ RGS8 > RGS7), provide evidence for the
predicted mechanism of the peptide, and show activity in a native
cell system. Additional research will clearly be needed to enhance
the potency of the peptides, more completely define the RGS spe-
cificity, and to develop RGS inhibitors that are cell-permeable for
more general use beyond patch-clamp approaches.
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